366 related articles for article (PubMed ID: 28138029)
1. Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-
Hou Z; Gattoc L; O'Connor C; Yang S; Wallace-Povirk A; George C; Orr S; Polin L; White K; Kushner J; Morris RT; Gangjee A; Matherly LH
Mol Cancer Ther; 2017 May; 16(5):819-830. PubMed ID: 28138029
[TBL] [Abstract][Full Text] [Related]
2. Folate transporter dynamics and therapy with classic and tumor-targeted antifolates.
O'Connor C; Wallace-Povirk A; Ning C; Frühauf J; Tong N; Gangjee A; Matherly LH; Hou Z
Sci Rep; 2021 Mar; 11(1):6389. PubMed ID: 33737637
[TBL] [Abstract][Full Text] [Related]
3. 6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.
Wang L; Wallace A; Raghavan S; Deis SM; Wilson MR; Yang S; Polin L; White K; Kushner J; Orr S; George C; O'Connor C; Hou Z; Mitchell-Ryan S; Dann CE; Matherly LH; Gangjee A
J Med Chem; 2015 Sep; 58(17):6938-59. PubMed ID: 26317331
[TBL] [Abstract][Full Text] [Related]
4. Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.
Saito S; Koya Y; Kajiyama H; Yamashita M; Kikkawa F; Nawa A
Cancer Sci; 2020 May; 111(5):1794-1804. PubMed ID: 32154964
[TBL] [Abstract][Full Text] [Related]
5. Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates.
Wilson MR; Hou Z; Yang S; Polin L; Kushner J; White K; Huang J; Ratnam M; Gangjee A; Matherly LH
Mol Pharmacol; 2016 Apr; 89(4):425-34. PubMed ID: 26837243
[TBL] [Abstract][Full Text] [Related]
6. Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
Ravindra M; Wilson MR; Tong N; O'Connor C; Karim M; Polin L; Wallace-Povirk A; White K; Kushner J; Hou Z; Matherly LH; Gangjee A
J Med Chem; 2018 May; 61(9):4228-4248. PubMed ID: 29701475
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy of pyrrolo[2,3-d]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment.
Wallace-Povirk A; Rubinsak L; Malysa A; Dzinic SH; Ravindra M; Schneider M; Glassbrook J; O'Connor C; Hou Z; Kim S; Back J; Polin L; Morris RT; Gangjee A; Gibson H; Matherly LH
Sci Rep; 2022 Jul; 12(1):11346. PubMed ID: 35790779
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter.
Kugel Desmoulin S; Wang L; Hales E; Polin L; White K; Kushner J; Stout M; Hou Z; Cherian C; Gangjee A; Matherly LH
Mol Pharmacol; 2011 Dec; 80(6):1096-107. PubMed ID: 21940787
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.
Wang L; Cherian C; Desmoulin SK; Polin L; Deng Y; Wu J; Hou Z; White K; Kushner J; Matherly LH; Gangjee A
J Med Chem; 2010 Feb; 53(3):1306-18. PubMed ID: 20085328
[TBL] [Abstract][Full Text] [Related]
10. Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
Ravindra M; Wallace-Povirk A; Karim MA; Wilson MR; O'Connor C; White K; Kushner J; Polin L; George C; Hou Z; Matherly LH; Gangjee A
J Med Chem; 2018 Mar; 61(5):2027-2040. PubMed ID: 29425443
[TBL] [Abstract][Full Text] [Related]
11. Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter.
Desmoulin SK; Wang L; Polin L; White K; Kushner J; Stout M; Hou Z; Cherian C; Gangjee A; Matherly LH
Mol Pharmacol; 2012 Oct; 82(4):591-600. PubMed ID: 22740639
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.
Wang L; Desmoulin SK; Cherian C; Polin L; White K; Kushner J; Fulterer A; Chang MH; Mitchell-Ryan S; Stout M; Romero MF; Hou Z; Matherly LH; Gangjee A
J Med Chem; 2011 Oct; 54(20):7150-64. PubMed ID: 21879757
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter.
Cherian C; Kugel Desmoulin S; Wang L; Polin L; White K; Kushner J; Stout M; Hou Z; Gangjee A; Matherly LH
Cancer Chemother Pharmacol; 2013 Apr; 71(4):999-1011. PubMed ID: 23412628
[TBL] [Abstract][Full Text] [Related]
14. Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
Golani LK; Wallace-Povirk A; Deis SM; Wong J; Ke J; Gu X; Raghavan S; Wilson MR; Li X; Polin L; de Waal PW; White K; Kushner J; O'Connor C; Hou Z; Xu HE; Melcher K; Dann CE; Matherly LH; Gangjee A
J Med Chem; 2016 Sep; 59(17):7856-76. PubMed ID: 27458733
[TBL] [Abstract][Full Text] [Related]
15. Determinants of the activities of antifolates delivered into cells by folate-receptor-mediated endocytosis.
Zhao R; Visentin M; Goldman ID
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1163-73. PubMed ID: 25847479
[TBL] [Abstract][Full Text] [Related]
16. Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors.
Desmoulin SK; Wang Y; Wu J; Stout M; Hou Z; Fulterer A; Chang MH; Romero MF; Cherian C; Gangjee A; Matherly LH
Mol Pharmacol; 2010 Oct; 78(4):577-87. PubMed ID: 20601456
[TBL] [Abstract][Full Text] [Related]
17. Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy.
Azaïs H; Queniat G; Bonner C; Kerdraon O; Tardivel M; Jetpisbayeva G; Frochot C; Betrouni N; Collinet P; Mordon S
Int J Gynecol Cancer; 2015 Sep; 25(7):1194-200. PubMed ID: 26244757
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
Golani LK; Islam F; O'Connor C; Dekhne AS; Hou Z; Matherly LH; Gangjee A
Bioorg Med Chem; 2020 Jun; 28(12):115544. PubMed ID: 32503687
[TBL] [Abstract][Full Text] [Related]
19. The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.
Matherly LH; Wilson MR; Hou Z
Drug Metab Dispos; 2014 Apr; 42(4):632-49. PubMed ID: 24396145
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.
Golani LK; George C; Zhao S; Raghavan S; Orr S; Wallace A; Wilson MR; Hou Z; Matherly LH; Gangjee A
J Med Chem; 2014 Oct; 57(19):8152-66. PubMed ID: 25234128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
